Pharma R&D Today

Ideas and Insight supporting all stages of Drug Discovery & Development

Select category
Search this blog

Compound Discovery May Spur Therapies for Autoimmune Conditions

Posted on December 20th, 2017 by

Pharma R&D

diabetes-2994808_640

People who develop autoimmune often suffer from their effects for the rest of their lives, frustrated by the lack of cure. Though there are various treatments available to help manage some of these conditions, they often don’t work very well and the disease continues to take a major toll on the patient and his or her quality of life. Continue reading “Compound Discovery May Spur Therapies for Autoimmune Conditions” »

How Pharma Can Make the Most of Gene Tech CRISPR

Posted on December 18th, 2017 by

Pharma R&D

puzzle-2500333_960_720

The gene-editing technology CRISPR, which stands for ‘clustered regularly interspaced short palindromic repeats,’ is one of today’s most-talked-about scientific innovations. In just a few years, it’s gone from being a barely known entity to becoming a regular presence in scientific literature. Continue reading “How Pharma Can Make the Most of Gene Tech CRISPR” »

Chemists Concerned About How Their Field is Viewed

Posted on December 13th, 2017 by

Chemistry

Chemistry Opinion Survey 2017-12-11 15-06-07

Chemistry and its importance in everyday life is often underrated at best, and wildly misunderstood at worst. The stock image of scientists in white lab coats holding beakers of toxic chemicals has been hard to shake Continue reading “Chemists Concerned About How Their Field is Viewed” »

As The Hive Evolves, More Companies Prepare to Join the Program

Posted on December 11th, 2017 by

Pharma R&D

Elsevier Reset Therapies 10

This year, four companies working in early-stage drug development were able to power their efforts with an array of Elsevier tools by participating in The Hive. Now, more promising pharma and biotech start-ups are in the process of entering into The Hive Continue reading “As The Hive Evolves, More Companies Prepare to Join the Program” »

Extreme Makeover: Clinical Trials Edition

Posted on December 4th, 2017 by

Pharma R&D

apple-watch-1694985_960_720

In a piece featured in the PharmaTimes, Katrina Megget points out the sad state of affairs when it comes to clinical trials, highlighting some appalling stats on the frequent failure to reach enrollment targets (in some cases, not finding any patients at all) and the tendency for studies to go on far longer than anticipated. Continue reading “Extreme Makeover: Clinical Trials Edition” »

Pills Have Gone Digital

Posted on November 24th, 2017 by

Pharma R&D

medicine-2520463_960_720

Paranoiacs and conspiracy theorists beware – the digital pill is here. The U.S. Food and Drug Administration announced on November 13 that it had approved Abilify MyCite (aripiprazole tablets with sensors), the first drug in America to have a digital ingestion tracking system. Continue reading “Pills Have Gone Digital” »

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 54


About this Blog

iStock_000019748868_Full

The Elsevier Pharma R&D blog provides insight and opinion on topics related to pharmaceutical research and development, namely: big data, target identification, new drug discovery, drug safety monitoring, risk mitigation and regulatory compliance. We serve the community of chemists, scientists, drug safety specialists, educators and students interested in pharmaceutical R&D.

Editor’s note: The views and opinions expressed are those of the author and do not necessarily reflect the views of Elsevier,  its affiliates and sponsors or its parent company, Reed Elsevier.